Pill To Ward Off COVID-19 Falls Short

Sell in May? | Pfizer COVID, Cancer Drugs Key to Top-Line GrowthPfizer COVID, Cancer Drugs Key to Top-Line Growth | Created for {EMAIL} | [Web Version]( May 2, 2022 CONNECT WITH KIPLINGER  [LinkedIn]( [Facebook]( [Twitter]( [Instagram ]( [Youtube]( [SIGN UP]( ⋅ [WEBSITE]( [] What's in the Works [] The COVID-19 pill Paxlovid failed to prevent infections in a recent study, according to Pfizer ([PFE](), but it is still being recommended as a treatment for those with COVID-19.Some experts were disappointed at the results, but not surprised, since the biology of preventing infection is different from that of treating infection. That means that Paxlovid can still be effective at preventing severe symptoms after infection. Moderna ([MRNA]() will deliver a large amount of its vaccine that targets the omicron variant of COVID-19 in preparation for a vaccination campaign this fall. Evidence on the effectiveness of the targeted vaccine should be available in the next month or two. [The Open Finance Impact]( Open finance enables secure, consent-based sharing of and access to financial capabilities, data, and account information. Join this webinar to hear a panel of open finance experts discuss trends and real-world open finance success stories. [READ MORE]( ADVERTISEMENT [] Latest [] Sell in May and go away? (Part 2): As we pointed out last week, we’ve hit “Sell in May” season: the time each year when Wall Street strategists and financial media ponder what exactly investors should do during the next six months, which, for stock-market performance, have been typically lackluster. The latest argument comes from LPL Chief Market Strategist Ryan Detrick, who notes that the historically weak period hasn’t actually been so bad of late. “Maybe we should call it ‘Sell in June,’” he says, as “May has been really strong lately (but then again, so had April).” Indeed, across the past nine Mays, the S&P 500 Index has been up eight times for an overall average gain of 0.9% – an average that’s weighed down by a 6.6% decline in 2019. Similarly, the six-month period between May and October has only been down once over the past 10 years (in 2015, by a mere 0.3%), averaging a respectable 5.7% increase. That’s all the more reason for us to stick with our advice: [Most buy-and-hold investors are better off holding through “Sell in May”]( and leaving the market timing to professionals who are paid to squeeze out every basis point of performance they can. Free download, [The Kiplinger Letter's Forecast](. No information required from you. [The Billion Dollar Startup Disrupting the $27T Retirement Industry]( With 110 million Americans over age 50, it's no wonder this Princeton grad's startup raised over $161M to help people plan for an easier retirement. [READ MORE]( ADVERTISEMENT [] Also on Kiplinger [] - [3 Reasons I Like Municipal Bonds]( - [4 Steps to Build a Resilient Financial Life]( - [HSA Contribution Limits and Other Requirements]( - [Pfizer COVID, Cancer Drugs Key to Top-Line Growth]( - [Build a Better Portfolio for 2022 -- Sign Up for Kiplinger's Free Investing E-Newsletters]( ABOUT KIPLINGER When we write about money, we get it right. So the decisions you make with your dollars are also right. Since 1920, Kiplinger has earned a reputation as a trusted provider of unbiased financial advice, objective business and economic forecasts, and practical help to millions of business professionals, investors, and individuals seeking to make more profitable decisions with their money. Our [flagship publications]( include Kiplinger’s Personal Finance magazine, The Kiplinger Letter, The Kiplinger Tax Letter, Kiplinger’s Retirement Report, and Kiplinger’s Investing for Income. All are regarded as the leading publications in their respective fields. Every day, millions of readers rely on our [free e-newsletters]( and [podcasts]( for help on everything from getting the best rate on a mortgage or car loan, to managing their businesses in an uncertain world, avoiding an IRS audit, building wealth for a secure retirement, or investing wisely in any kind of market. Now it’s your turn to reap all the rewards Kiplinger has to offer. Visit [Kiplinger.com](, your gateway to all of the above and much more. Check in any time for our latest advice on how to make more money, and keep more of the money you make. Stay right on the money, with Kiplinger. [Sign Up]( | [Print Publications]( | [Unsubscribe]( [Privacy Policy]( | [Cookies Policy]( | [Terms and Conditions]( CONTACT US: [FEEDBACK](concat('mailto:',$brief_feedback_email)) | [ADVERTISE]( Future US LLC © 1100 13th St. NW, Suite 1000, Washington, DC 20005